360 related articles for article (PubMed ID: 25518854)
1. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
[TBL] [Abstract][Full Text] [Related]
2. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
[TBL] [Abstract][Full Text] [Related]
3. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
[TBL] [Abstract][Full Text] [Related]
4. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.
Sandén P; Renlund H; Svensson PJ; Själander A
Thromb Haemost; 2017 Jan; 117(1):27-32. PubMed ID: 27652593
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
[TBL] [Abstract][Full Text] [Related]
6. Prediction Score for Anticoagulation Control Quality Among Older Adults.
Lin KJ; Singer DE; Glynn RJ; Blackley S; Zhou L; Liu J; Dube G; Oertel LB; Schneeweiss S
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982676
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
[TBL] [Abstract][Full Text] [Related]
8. New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
Goto S; Goto S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Haas S; Parkhomenko A; Oto A; Misselwitz F; Turpie AGG; Verheugt FWA; Fox KAA; Gersh BJ; Kakkar AK
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):301-309. PubMed ID: 31821482
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
10. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of point of care coagulometers compared to reference laboratory measurements in patients on oral anticoagulation therapy.
Dillinger JG; Si Moussi T; Berge N; Bal Dit Sollier C; Henry P; Drouet L
Thromb Res; 2016 Apr; 140():66-72. PubMed ID: 26901852
[TBL] [Abstract][Full Text] [Related]
12. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
[TBL] [Abstract][Full Text] [Related]
13. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
[TBL] [Abstract][Full Text] [Related]
14. Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study.
Biedermann JS; van Rein N; van den Besselaar AM; Buhre PN; de Maat MP; van der Meer FJ; Leebeek FW; Kruip MJ
J Thromb Haemost; 2016 Apr; 14(4):695-703. PubMed ID: 26806724
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
[TBL] [Abstract][Full Text] [Related]
16. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
[TBL] [Abstract][Full Text] [Related]
17. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
19. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
20. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
